ARTHEx Biotech

Executive Summary

ARTHEx Biotech is a private Spanish biotechnology company spun out from the University of Valencia in 2019, specializing in antisense RNA (anti-miR) therapies for genetic diseases with high unmet medical need. Its lead program targets myotonic dystrophy type 1 (DM1), a debilitating neuromuscular disorder with no approved disease-modifying therapies. The company's approach utilizes proprietary antisense oligonucleotides to block pathogenic microRNAs, aiming to restore normal gene expression. ARTHEx has demonstrated promising preclinical efficacy in DM1 models and is advancing toward clinical development. With a strong intellectual property portfolio and a focus on rare genetic disorders, ARTHEx represents a potential breakthrough in RNA-targeted therapeutics. The company is currently in the preclinical stage and is expected to initiate first-in-human studies within the next 12–18 months, pending regulatory approvals and financing.

Upcoming Catalysts (preview)

• Q3 2026IND Filing for DM1 Program70% success
• Q2 2026Preclinical Data Presentation at Scientific Conference85% success
• Q4 2026Series A Financing Round65% success